BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Jayne D. Complement inhibition in ANCA vasculitis. Nephrol Ther 2019;15:409-12. [PMID: 31631015 DOI: 10.1016/j.nephro.2019.04.001] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
Number Citing Articles
1 Tampe D, Baier E, Hakroush S, Tampe B. Low serum levels of complement C3c at diagnosis indicate poor outcome in ANCA-associated glomerulonephritis. Kidney International Reports 2022. [DOI: 10.1016/j.ekir.2021.12.038] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
2 Trivioli G, Vaglio A. The rise of complement in ANCA-associated vasculitis: from marginal player to target of modern therapy. Clin Exp Immunol 2020;202:403-6. [PMID: 32946609 DOI: 10.1111/cei.13515] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
3 Hakroush S, Tampe D, Korsten P, Ströbel P, Tampe B. Complement Components C3 and C4 Indicate Vasculitis Manifestations to Distinct Renal Compartments in ANCA-Associated Glomerulonephritis. Int J Mol Sci 2021;22:6588. [PMID: 34205415 DOI: 10.3390/ijms22126588] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
4 Moiseev S, Lee JM, Zykova A, Bulanov N, Novikov P, Gitel E, Bulanova M, Safonova E, Shin JI, Kronbichler A, Jayne DRW. The alternative complement pathway in ANCA-associated vasculitis: further evidence and a meta-analysis. Clin Exp Immunol 2020;202:394-402. [PMID: 32691878 DOI: 10.1111/cei.13498] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
5 Zipfel PF, Wiech T, Gröne HJ, Skerka C. Complement catalyzing glomerular diseases. Cell Tissue Res 2021;385:355-70. [PMID: 34613485 DOI: 10.1007/s00441-021-03485-w] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
6 Chen M, Edwards SR, Reutens DC. Complement in the Development of Post-Traumatic Epilepsy: Prospects for Drug Repurposing. J Neurotrauma 2020;37:692-705. [PMID: 32000582 DOI: 10.1089/neu.2019.6942] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
7 d’Alessandro M, Conticini E, Bergantini L, Cameli P, Cantarini L, Frediani B, Bargagli E. Neutrophil Extracellular Traps in ANCA-Associated Vasculitis and Interstitial Lung Disease: A Scoping Review. Life 2022;12:317. [DOI: 10.3390/life12020317] [Reference Citation Analysis]
8 Sciascia S, Ponticelli C, Roccatello D. Pathogenesis-based new perspectives of management of ANCA-associated vasculitis. Autoimmun Rev 2021;:103030. [PMID: 34971805 DOI: 10.1016/j.autrev.2021.103030] [Reference Citation Analysis]